Correction: S100A9+ MDSC and TAM-mediated EGFR-TKI resistance in lung adenocarcinoma: the role of RELB

Po-Hao Feng; Chih-Teng Yu; Kuan-Yuan Chen; Ching-Shan Luo; Shen Ming Wu; Chien-Ying Liu; Lu Wei Kuo; Yao-Fei Chan; Tzu-Tao Chen; Chih-Cheng Chang; Chun-Nin Lee; Hsiao-Chi Chuang; Chiou-Feng Lin; Chia-Li Han; Wei-Hwa Lee; Kang-Yun Lee

doi:10.18632/oncotarget.25943

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: S100A9+ MDSC and TAM-mediated EGFR-TKI resistance in lung adenocarcinoma: the role of RELB

PDF | How to cite

Oncotarget. 2018; 9:31559-31559. https://doi.org/10.18632/oncotarget.25943

Metrics: PDF 1863 views | ?

Po-Hao Feng^1,2, Chih-Teng Yu³, Kuan-Yuan Chen^1,4, Ching-Shan Luo¹, Shen Ming Wu¹, Chien-Ying Liu³, Lu Wei Kuo¹, Yao-Fei Chan³, Tzu-Tao Chen¹, Chih-Cheng Chang¹, Chun-Nin Lee¹, Hsiao-Chi Chuang⁵, Chiou-Feng Lin⁶, Chia-Li Han⁷, Wei- Hwa Lee8 and Kang-Yun Lee^1,2

¹ Division of Pulmonary Medicine, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, Taipei, Taiwan
² Division of Thoracic Medicine, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
³ Division of Pulmonary Medicine, Department of Internal Medicine, Chang Gung Medical Foundation Linko Branch, Taoyuan, Taiwan
⁴ Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
⁵ School of Respiratory Therapy, College of Medicine, Taipei Medical University, Taipei, Taiwan
⁶ Department of Microbiology and Immunology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
⁷ Master Program for Clinical Pharmacogenomics and Pharmacoproteomics, College of Pharmacy, Taipei Medical University, Taipei, Taiwan
⁸ Department of Pathology, Shuang Ho Hospital, Taipei Medical University, Taipei, Taiwan

Published: July 31, 2018

This article has been corrected: The correct funding information is listed below:

This study was supported by National Science Council (NSC 102-2314-B-038-048) to PHF, Ministry of Science and Technology (MOST 103-2314-B-038 -056 and 104-2314-B-038-070) to PHF, and Taipei Medical University (TMU103- AE1-B31, TMU103-AE2-I01-3, 103TMU-SHH-01-2, 105TMU-SHH-02-2) to PHF.

Original article: Oncotarget. 2018; 9:7631-7643. DOI: https://doi.org/10.18632/oncotarget.24146.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 25943

Publication Alerts

Corrections:

Correction: S100A9+ MDSC and TAM-mediated EGFR-TKI resistance in lung adenocarcinoma: the role of RELB